Scholarlink

Objective <p>This research aimed at evaluating the effectiveness and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis (RA).</p> Methods <p>In this randomized controlled parallel study, 90 patients with active RA were randomized into three groups; group 1 (control group; <i>n</i> = 30) which received traditional therapy, group 2 (Nitazoxanide group; <i>n</i> = 30) which received traditional therapy plus 1 gm/day oral nitazoxanide, and group 3 (Escitalopram group; <i>n</i> = 30) which received traditional therapy plus 10&#xa0;mg/day oral escitalopram for three months. At baseline and 3&#xa0;months after treatment, clinical and functional assessments were done through the 28-joint count disease activity score using C-reactive protein (DAS28-CRP), the health assessment questionnaire-disability index (HAQ-DI), and the patient’s global assessment (PGA). Also, serum levels of high-sensitivity C-reactive protein (hs-CRP), signal transducer and activator of transcription-3 (STAT-3), Janus kinase-2 (JAK-2), toll-like receptors 4 (TLR-4), interleukin-1 beta (IL-1β), and malondialdehyde (MDA) were assessed. Data were analyzed using paired <i>t</i>-test and one-way analysis of variance, followed by Tukey’s HDS test.</p> Results <p>Three months after treatment and as compared to the control group, the nitazoxanide group showed a significant decline in PGA (<i>P</i> = 0.042), and serum levels of STAT-3 (<i>P</i> &lt; 0.001), JAK-2 (<i>P</i> &lt; 0.001), TLR-4 (<i>P</i> &lt; 0.001), and IL-1β (<i>P</i> &lt; 0.001). On the other hand, the escitalopram group produced a significant decrease in DAS28-CRP score (<i>P</i> = 0.029), HAQ-DI score (<i>P</i> = 0.001), and serum levels of JAK-2 (<i>P</i> = 0.001), TLR-4 (<i>P</i> &lt; 0.001), IL-1β (<i>P</i> &lt; 0.001), and MDA (<i>P</i> &lt; 0.001). As compared to nitazoxanide group, the escitalopram group produced a significant decline in fatigue score (<i>P</i> &lt; 0.001) and serum levels of both IL-1β (<i>P</i> = 0.023) and MDA (<i>P</i> &lt; 0.001). Both medications were safe; however, chromaturia was the only significant nitazoxanide-related adverse effect.</p> Conclusion <p>Nitazoxanide and escitalopram could serve as potential adjuvant therapies for patients with RA based on their effectiveness and safety data.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis: a randomized controlled study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月9日

查看全文
  • Tarek M. Mostafa,
  • Abeer A. El-Sayed,
  • Abdel Moaty A. Afifi,
  • Dalia R. El-Afify

摘要

Objective

This research aimed at evaluating the effectiveness and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis (RA).

Methods

In this randomized controlled parallel study, 90 patients with active RA were randomized into three groups; group 1 (control group; n = 30) which received traditional therapy, group 2 (Nitazoxanide group; n = 30) which received traditional therapy plus 1 gm/day oral nitazoxanide, and group 3 (Escitalopram group; n = 30) which received traditional therapy plus 10 mg/day oral escitalopram for three months. At baseline and 3 months after treatment, clinical and functional assessments were done through the 28-joint count disease activity score using C-reactive protein (DAS28-CRP), the health assessment questionnaire-disability index (HAQ-DI), and the patient’s global assessment (PGA). Also, serum levels of high-sensitivity C-reactive protein (hs-CRP), signal transducer and activator of transcription-3 (STAT-3), Janus kinase-2 (JAK-2), toll-like receptors 4 (TLR-4), interleukin-1 beta (IL-1β), and malondialdehyde (MDA) were assessed. Data were analyzed using paired t-test and one-way analysis of variance, followed by Tukey’s HDS test.

Results

Three months after treatment and as compared to the control group, the nitazoxanide group showed a significant decline in PGA (P = 0.042), and serum levels of STAT-3 (P < 0.001), JAK-2 (P < 0.001), TLR-4 (P < 0.001), and IL-1β (P < 0.001). On the other hand, the escitalopram group produced a significant decrease in DAS28-CRP score (P = 0.029), HAQ-DI score (P = 0.001), and serum levels of JAK-2 (P = 0.001), TLR-4 (P < 0.001), IL-1β (P < 0.001), and MDA (P < 0.001). As compared to nitazoxanide group, the escitalopram group produced a significant decline in fatigue score (P < 0.001) and serum levels of both IL-1β (P = 0.023) and MDA (P < 0.001). Both medications were safe; however, chromaturia was the only significant nitazoxanide-related adverse effect.

Conclusion

Nitazoxanide and escitalopram could serve as potential adjuvant therapies for patients with RA based on their effectiveness and safety data.